信邦制药补缴税款及滞纳金5078.69万元

Core Viewpoint - Xinfang Pharmaceutical (002390.SZ) disclosed a tax payment and late fee of 50.7869 million yuan, which will negatively impact its 2025 financial performance [2] Group 1: Financial Impact - The company needs to pay 5.07869 million yuan in tax and late fees, with 2.6957 million yuan attributed to the company and 48.0912 million yuan to its subsidiaries [2] - The tax payment and late fees will be included in Xinfang Pharmaceutical's 2025 profit and loss statement [2] - For the first three quarters of 2025, the company's revenue was 4.266 billion yuan, a year-on-year decrease of 6.55%, and the net profit attributable to shareholders was 152 million yuan, a year-on-year decrease of 13.74% [2] Group 2: Business Overview - Xinfang Pharmaceutical's main business includes medical services, pharmaceutical distribution, and pharmaceutical manufacturing [2] - The company is a leading pharmaceutical distributor in Guizhou Province, with key medical institutions including Guizhou Medical University Affiliated Tumor Hospital, Guizhou Medical University Affiliated Baiyun Hospital, and Guizhou Medical University Affiliated Wudang Hospital [2] Group 3: Legal Issues - Recently, the People's Procuratorate of Kaiyang County, Guizhou Province, has filed a public prosecution against Xinfang Pharmaceutical for alleged corporate bribery [2]